Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns.

Published

Journal Article

INTRODUCTION: Digital microfluidics (DMF) is an emerging technology with the appropriate metrics for application to newborn and high-risk screening for inherited metabolic disease and other conditions that benefit from early treatment. Areas covered: This review traces the development of electrowetting-based DMF technology toward the fulfillment of its promise to provide an inexpensive platform to conduct enzymatic assays and targeted biomarker assays at the bedside. The high-throughput DMF platform, referred to as SEEKER®, was recently authorized by the United States Food and Drug Administration to screen newborns for four lysosomal storage disorders (LSDs) and is deployed in newborn screening programs in the United States. The development of reagents and methods for LSD screening and results from screening centers are reviewed. Preliminary results from a more compact DMF device, to perform disease-specific test panels from small volumes of blood, are also reviewed. Literature for this review was sourced using principal author and subject searches in PubMed. Expert commentary: Newborn screening is a vital and highly successful public health program. DMF technology adds value to the current testing platforms that will benefit apparently healthy newborns with underlying genetic disorders and infants at-risk for conditions that present with symptoms in the newborn period.

Full Text

Duke Authors

Cited Authors

  • Millington, D; Norton, S; Singh, R; Sista, R; Srinivasan, V; Pamula, V

Published Date

  • August 2018

Published In

Volume / Issue

  • 18 / 8

Start / End Page

  • 701 - 712

PubMed ID

  • 30004274

Pubmed Central ID

  • 30004274

Electronic International Standard Serial Number (EISSN)

  • 1744-8352

Digital Object Identifier (DOI)

  • 10.1080/14737159.2018.1495076

Language

  • eng

Conference Location

  • England